Rainbow Childrens Medicare

    RAINBOW
    Pharma
    ₹1,258.00
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹12,726 Cr

    P/E
    43.68
    Day range
    ₹1,250.00 – ₹1,293.00
    52-week range
    ₹1,084.00 – ₹1,610.00
    Volume
    77,140
    Open
    ₹1,293.00
    Prev close
    ₹1,270.40

    Latest results · Q2 FY27(consolidated)Revenue ₹548 Cr+23.2%Profit ₹84 Cr+10.9%Margin 15.3%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 54 / 100

    Factor percentiles

    Value38
    Quality55
    Momentum37
    Low volatility87

    Derived metrics

    Earn. yield
    2.3%
    Graham no.
    ₹328.98
    vs Graham
    -73.8%
    ROE ÷ P/B
    2.4%
    12-1 mom.
    -7.5%
    Return / vol
    -0.29
    Magic Formula
    #408
    Piotroski
    3/6
    FCF yield
    1.6%
    PEG
    3.99

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Rainbow Childrens MedicareRAINBOW₹12,726 Cr43.687.5618.1%17.0%31.0%0.56+23.1%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 10d ago

    Headlines about Rainbow Childrens Medicare from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    44.2
    Price / Book
    7.44
    ROE (FY26)
    18.1%
    ROCE (latest year)
    17%
    Dividend yield
    0.27%

    Moving averages (NSE)

    20-day
    ₹1,237.8
    Price above
    50-day
    ₹1,308.01
    Price below
    200-day
    ₹1,322.38
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +13.2%
    Profit 3Y CAGR
    +10.0%
    Revenue YoY (Sep 2026)
    +23.1%
    Profit YoY (Sep 2026)
    +10.5%
    Operating margin
    31.0%
    Net margin
    15.3%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr200 Cr400 Cr600 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • FII
    • Public
    • Others

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-500 Cr-250 Cr0 Cr250 Cr500 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr500 Cr1K Cr1.5K Cr2K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x1x2x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY24FY25FY26FY27₹0₹1₹2₹3₹4

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales336341330417398370353445445460470548
    Expenses218236236270264255249296298315335378
    Operating Profit11810694147134115104149147145135170
    OPM %35%31%28%35%34%31%29%33%33%31%29%31%
    Other Income91312111315208114138
    Interest141718181818181920202122
    Depreciation283234353534343640414245
    Profit before tax856953105947771102988784112
    Tax %26%26%26%25%27%27%25%26%24%10%26%25%
    Net Profit635140796957547674786384
    EPS in Rs₹6.12₹5.02₹3.89₹7.77₹6.76₹5.55₹5.27₹7.41₹7.14₹7.59₹5.96₹8.08

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days22

    -3 days since Mar 2021

    Inventory Days67

    +31 days since Mar 2021

    Days Payable162

    -28 days since Mar 2021

    Cash Conversion Cycle-73

    +57 days since Mar 2021

    Working Capital Days8

    +25 days since Mar 2021

    Strengths, risks & growth

    Rainbow Children's Medicare Limited operates a multi-specialty pediatric, obstetrics, and gynecology hospital chain in India. The company offers a wide range of services such as newborn and pediatric intensive care, pediatric multi-specialty services, pediatric quaternary care, obstetrics, and gynecology. [1] It is country’s largest pediatric hospital chain with 16 hospitals spread across 6 cities. [2]

    Strengths

    • Company's median sales growth is 22.8% of last 10 years

    Risks

    • Stock is trading at 7.57 times its book value

    Compounded Sales Growth

    10 Years
    +22%
    5 Years
    +21%
    3 Years
    +13%
    TTM
    +23%

    Compounded Profit Growth

    10 Years
    +31%
    5 Years
    +46%
    3 Years
    +7%
    TTM
    +16%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    +6%
    1 Year
    -2%

    Return on Equity

    10 Years
    +18%
    5 Years
    +20%
    3 Years
    +17%
    Last Year
    +17%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter49.84%49.84%49.84%49.83%-0.01 pp
    FII19.24%17.24%16.03%14.66%-1.37 pp
    DII19.49%21.12%22.56%23.28%+0.72 pp
    Public11.40%11.68%11.39%11.84%+0.45 pp
    Others0.04%0.12%0.18%0.40%+0.22 pp

    Filed with NSE for Sept 2026: promoters 49.83%, public 49.77%

    Analysts & fund holdings

    100%
    100% recommend buy
    14 analysts cover the stock
    Valuation vs Health Care Providers & Services
    P/E43.7 vs 45.1
    Sector P/B6.03
    Beta0.71

    Who holds the shares, quarter by quarter

    Mutual funds 18.91% (+0.35 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters50.0%
    • Foreign institutions14.7%
    • Mutual funds18.9%
    • Insurance2.8%
    • Other domestic institutions1.7%
    • Retail5.5%
    • Others6.3%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    ICICI Pru Large & Mid Cap Fund2.12%0.86%-0.28 pp
    Motilal Oswal Small Cap Fund1.52%2.35%-0.35 pp
    DSP Small Cap Fund1.46%0.92%-0.23 pp
    ICICI Pru Multi Asset Allocation Fund1.27%0.20%-0.04 pp
    Axis Small Cap Fund1.01%0.44%-0.10 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    23.1%
    Downside volatility
    22.2%
    Worst 5% of days
    2.4%
    Average of that tail
    3.0%
    Max drawdown (1Y)
    27.3%
    Below its peak
    21.3%

    Against the market

    Beta vs Nifty 50
    0.47
    Correlation
    0.27
    Relative strength (3M)
    -18.8%
    ATR (14)
    3.1%

    Return

    Return 1M
    +0.7%
    Return 3M
    -14.9%
    Return 6M
    -6.9%
    Return 1Y
    -6.8%
    vs 200-day average
    -4.9%

    Momentum

    RSI (14)
    48.0
    MACD histogram
    8.81
    Stochastic %K
    64.4
    ADX (14)
    22.4
    +DI / −DI
    15.5 / 17.3
    Money flow index
    65.3

    Participation

    Delivery (20d avg)
    54.3%
    vs its 60-day baseline
    -0.7 pts
    Volume vs 20-day
    -0.7σ
    Close vs day's VWAP
    -0.3%
    52-week position
    31 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    3 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — passed
    Free cash flow
    ₹203 Cr
    FCF yield
    1.6%
    Cash conversion
    1.49
    Accruals ratio
    -0.050
    Net debt
    ₹936 Cr
    Net debt / equity
    0.55
    EV / sales
    7.10
    PEG
    3.99
    Capex intensity
    12.7%
    Revenue CAGR
    29.9%
    Profit CAGR
    30.0%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹3.50

      Dividend - Rs 3.50 Per Share

      21 Jul 2026
      ex-date
    • dividend
      ₹3.00

      Dividend - Rs 3 Per Share

      27 Jun 2025
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/Dividend - Rs 3 Per Share

      23 Jul 2024
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/Dividend - Rs 3 Per Share

      22 Jun 2023
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend - Rs 2 Per Share

      7 Sept 2022
      ex-date

    Company announcements

    Company Update
    Intimation Of Execution Of Lease Agreement With APCRDA For Development Of A Children'S Hospital At Amravati, Andhra Pradesh.

    Intimation of execution of lease agreement with APCRDA.

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Credit Rating

    Credit Rating

    Insider Trading / SAST
    Closure of Trading Window

    Initimation for trading window closure for quarter and half year ended September 30, 2026

    Others
    Board Meeting Outcome for Outcome Of Board Meeting

    Outcome of Board Meeting for Appointment of Mr. Sudarshan Patodia as the Chief Financial Officer (KMP) of the Company and other general matters

    Company Update
    Intimation Of Contact Details Of Key Managerial Personnel Authorised Under Regulation 30(5) Of SEBI (LODR) Regulations, 2015

    Intimation of contact details of Key Managerial Personnel authorised under Regulation 30(5) of SEBI (LODR) Regulations, 2015

    Company Update
    Intimation For Grant Of Options

    Intimation for grant of options

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Appointment of Mr. Sudarshan Patodia as the Chief Financial Officer (KMP) of the Company

    Company Update
    Announcement Under Regulation 30 - Update On Commencement Of Operations At Guntur, Andhra Pradesh.

    Update on Commencement of Operations at Guntur, Andhra Pradesh.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Analyst/Institutional Investor Group Meetings.

    Company Update
    Announcement under Regulation 30 (LODR)-Cessation

    Resignation of Senior Management Personnel.

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Resignation of Mr. Vikas Maheshwari as Chief Financial Officer of the Company w.e.f. August 31, 2026

    Company Update
    Update On Acquisition

    Update on acquisition

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Earnings Call Transcript for the quarter ended June 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Link of Audio recording of Earnings Conference call for quarter ended June 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper publication of financial results for quarter ended June 30, 2026

    Filed with BSE (scrip 543524); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 1 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Rainbow Childrens Medicare: common questions

    Answered from the figures on this page.

    Rainbow Childrens Medicare last traded at ₹1,258.00 (NSE, as of 18 Nov 2026). The last session moved it down 0.98%.

    Rainbow Childrens Medicare is valued at about ₹12,726 crore (NSE, as of 18 Nov 2026).

    Rainbow Childrens Medicare trades at a price-to-earnings ratio of 43.68 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Rainbow Childrens Medicare has traded between ₹1,084.00 and ₹1,610.00 over the past 52 weeks, to 18 Nov 2026. It is currently 33% of the way up that range.

    Rainbow Childrens Medicare (RAINBOW) is classified under Pharma on this site's screener.